Search

USFDA Guidance: Amendments to Abbreviated New Drug Applications (ANDAs) Under GDUFA
FDA's Center for Drug Evaluation and Research revised the final guidance last week titled " ANDA Submissions | Amendments to Abbreviated...

Sharan Murugan
Sep 15, 20242 min read
64 views
0 comments


USFDA Guidance: Facility Readiness: Goal Date Decisions Under GDUFA
The US FDA has released final guidance for industry applicants "Facility Readiness: Goal Date Decisions Under GDUFA" which helps assign...

Sharan Murugan
Jun 20, 20242 min read
51 views
0 comments


USFDA Guidance: Requests for Reconsideration under GDUFA
The U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research...

Sharan Murugan
Jan 13, 20242 min read
32 views
0 comments


USFDA Guidance: Assessing User Fees Under the GDUFA of 2022
Today (09 June 2023) the USFDA's Center for Drug Evaluation and Research (CDER) released updated final guidance on "Assessing User Fees...

Sharan Murugan
Jun 8, 20231 min read
20 views
0 comments


USFDA Guidance: Product-Specific Guidance Meetings Between FDA and ANDA Applicants
The Food and Drug Administration published a new draft guidance for the industry on February 17, 2023, titled "Product-Specific Guidance...

Sharan Murugan
Feb 19, 20232 min read
35 views
0 comments


USFDA Guidance: ANDA Submissions – Prior Approval Supplements - Under GDUFA
Center for Drug Evaluation and Research (CDER) finalized and released updated guidance on "ANDA Submissions – Prior Approval Supplements...
Sharan Murugan
Oct 17, 20221 min read
234 views
1 comment


USFDA Guidance : GDUFA III User Fees & 4 Generic Drug related Guidances
USFDA finalized and released four Guidelines yesterday (05 October 2022), in accordance with the time frames set forth in the Generic...
Sharan Murugan
Oct 6, 20222 min read
87 views
0 comments